What dose of vitamin K should be administered to a patient on warfarin with an INR of 7.37 who is not actively bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vitamin K Dosing for INR 7.37 Without Bleeding

For a patient on warfarin with an INR of 7.37 and no active bleeding, administer 1 to 2.5 mg of oral vitamin K and hold 1-2 doses of warfarin. This approach will safely lower the INR into a therapeutic range within 24 hours while avoiding warfarin resistance and minimizing bleeding risk.

Rationale and Evidence-Based Approach

Your patient's INR of 7.37 falls into the 5-9 range, which is the critical decision point for vitamin K administration. The American College of Chest Physicians guidelines specifically address this scenario 1:

Why Vitamin K is Indicated

  • INR between 5-9 without bleeding: The guidelines recommend either holding warfarin alone OR holding warfarin plus vitamin K 1-2.5 mg orally 1
  • The vitamin K approach should be used if the patient has ANY increased bleeding risk 1, including:
    • Age ≥65 years
    • History of stroke or GI bleeding
    • Renal insufficiency or anemia
    • Concomitant antiplatelet agents or NSAIDs
    • Recent trauma risk

Dosing Specifics

Oral vitamin K 1-2.5 mg is the optimal dose for INR 5-9 1. The evidence supporting this:

  • A prospective study of 62 warfarin patients with INR 4-10 showed that 1 mg oral vitamin K lowered INR to <4 in 85% of patients and to <1.9 in 35% within 24 hours 1
  • No patients developed warfarin resistance when resuming therapy 1
  • Oral administration is "predictably effective and has the advantages of convenience and safety over parenteral routes" 1

Route of Administration

Oral is strongly preferred over IV or subcutaneous 1:

  • IV vitamin K carries risk of anaphylactic reactions 1
  • Subcutaneous absorption is "unpredictable and sometimes delayed" 1
  • Oral vitamin K achieves INR reduction within 24 hours, which is adequate for non-bleeding patients 1

Important Clinical Considerations

When NOT to Give Vitamin K

The 2012 ACCP guidelines actually suggest against routine vitamin K use for INR 4.5-10 without bleeding 2. However, this recommendation is Grade 2B (weak) and based on studies showing no difference in major bleeding outcomes between vitamin K and withholding warfarin alone. The key nuance: vitamin K doesn't reduce bleeding risk in low-risk patients, but it DOES lower INR faster 2.

Risk Stratification Matters

At INR 7.37, your patient is at the higher end of the 5-9 range where bleeding risk increases substantially. The guidelines note that "risk of bleeding increases when the INR exceeds 4, and the risk rises sharply with values ≥5" 1. Given this INR level, vitamin K administration is prudent unless the patient is truly low-risk (young, no comorbidities, no fall risk, no concurrent antiplatelet therapy).

Avoid Higher Doses

Do NOT use 5 mg or higher doses for this INR level 1:

  • Doses of 5 mg are reserved for INR >10 1
  • High doses (10 mg) "may lower the INR more than necessary and lead to warfarin resistance for up to a week" 1

Monitoring and Follow-Up

  • Recheck INR in 24 hours 1
  • If INR remains elevated, consider additional 1-2 mg vitamin K 1
  • Resume warfarin at a lower maintenance dose once INR approaches therapeutic range 1
  • Investigate the cause of INR elevation (dietary changes, medication interactions, illness) 1

Common Pitfalls to Avoid

  1. Don't use IV vitamin K unless rapid reversal is critical for urgent surgery—it's unnecessary for non-bleeding patients and carries anaphylaxis risk 1
  2. Don't give 5-10 mg doses—this is excessive for INR <10 and increases warfarin resistance 1
  3. Don't skip vitamin K in high-risk patients—while guidelines suggest against routine use, clinical judgment should prevail for patients with bleeding risk factors 1, 2
  4. Don't forget to hold warfarin doses—vitamin K alone without holding warfarin is insufficient 1

References

Related Questions

After a supratherapeutic INR >8 treated with vitamin K, the patient’s INR is now 1.2; what warfarin dose should be resumed?
What is the appropriate vitamin K dosing for a patient with an INR of 7.49?
What is the appropriate vitamin K dose for a patient with an INR of 9.03?
In a 68-year-old patient on warfarin for atrial fibrillation, how should the INR be managed and when is vitamin K indicated?
When should vitamin K be administered based on the International Normalized Ratio (INR)?
In a catheterized patient currently receiving oral amoxicillin‑clavulanate, who also has a red, swollen, warm leg and is on prednisone, how should a urinary tract infection be managed when the urinalysis shows no white blood cells?
In a 12-year-old patient with ADHD who is experiencing auditory hallucinations while taking valproic acid (Depakote) 500 mg and risperidone 0.25 mg, which worsened her symptoms, what is the next step in management?
In a patient with chronic kidney disease who has a serum iron of 5 µg/dL and low ferritin, is intravenous iron indicated?
Would cardioversion be effective in a patient with continuous atrial fibrillation for six months?
How should a 12-year-old with disruptive mood dysregulation disorder, severe aggression, and suicidal ideation who is currently taking valproic acid and risperidone be managed?
In a patient with recent pancreatic cyst evaluation (EGD and axially placed stent) and recent pulmonary embolism who now presents with fever of 101.8°F, cough that worsens when supine, brief sharp abdominal pain, otherwise normal vital signs, and a pending CBC, what additional assessments and investigations should be ordered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.